VYJUVEK
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for Neurotrophic Keratitis
Krystal Biotech; FDA; platform technology designation; HSV-1 viral vector; KB801; gene therapy; neurotrophic keratitis; redesable eye drop; VYJUVEK